肾
纤维化
利基
细胞生物学
癌症研究
化学
生物
肾脏疾病
医学
HEK 293细胞
信号转导
细胞生长
作者
Junxin Huang,Zifu Yao,Yuxi Zhang,Shihui Lin,Jing Li,Fan Fan Hou,Ying Liu,Li Li
标识
DOI:10.1016/j.jare.2026.06.023
摘要
INTRODUCTION: Kidney fibrosis is a common pathological pathway of chronic kidney disease (CKD), driven by the formation of fibrogenic niche. Fibroblasts undergo proliferation and activation in this specialized microenvironment, but the precise mechanism by which the fibrogenic niche modulates fibroblast behavior remains elusive. OBJECTIVES: This study aimed to clarify how fibrillin-1 (FBN1), a core structural component of the fibrogenic niche, governs fibroblast proliferation and activation. We further evaluated targeted disruption of the FBN1-EGFR interaction as a therapeutic strategy to block kidney fibrosis progression. METHODS: Spatial transcriptomics localized FBN1 within the fibrogenic niche. Validation was performed using decellularized kidney scaffolds (KTS), NRK-49F cells, and primary renal fibroblasts. Mechanistic studies included co-immunoprecipitation, RNA sequencing, and genetic knockdown models. Tubule-specific Fbn1 knockout mice provided in vivo evidence. High-throughput screening identified FBN1-EGFR disruptors. RESULTS: FBN1 was enriched in the fibrogenic niche and potently stimulated fibroblast activation. Mechanistically, tubule-derived FBN1 bound fibroblast EGFR, triggering persistent MAPK signaling that accelerated fibrosis. Pharmacological inhibition of EGFR/MAPK signaling blocked these effects. High-throughput screening revealed fucosterol as a potent FBN1-EGFR interaction disruptor that competitively blocked binding, subsequently suppressing MAPK activation and attenuating renal fibrosis. CONCLUSION: FBN1 acts as a core functional molecule to shape and maintain the fibrogenic niche, and further drives kidney fibrosis by activating the downstream EGFR/MAPK cascade within this niche. By disrupting the FBN1-EGFR interaction, fucosterol provides a promising therapeutic strategy for inhibiting fibrogenic niche formation and blocking kidney fibrosis progression at the source.
科研通智能强力驱动
Strongly Powered by AbleSci AI